153 related articles for article (PubMed ID: 12566593)
1. Dopaminergic modulation of visual-spatial working memory in Parkinson's disease.
Costa A; Peppe A; Dell'Agnello G; Carlesimo GA; Murri L; Bonuccelli U; Caltagirone C
Dement Geriatr Cogn Disord; 2003; 15(2):55-66. PubMed ID: 12566593
[TBL] [Abstract][Full Text] [Related]
2. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.
Costa A; Peppe A; Dell'Agnello G; Caltagirone C; Carlesimo GA
Neuropsychologia; 2009 Apr; 47(5):1374-81. PubMed ID: 19428401
[TBL] [Abstract][Full Text] [Related]
3. Dissociable effects of dopaminergic therapy on spatial versus non-spatial working memory in Parkinson's disease.
Mollion H; Ventre-Dominey J; Dominey PF; Broussolle E
Neuropsychologia; 2003; 41(11):1442-51. PubMed ID: 12849762
[TBL] [Abstract][Full Text] [Related]
4. Effects of Parkinson's disease and dopamine on digit span measures of working memory.
Grogan JP; Knight LE; Smith L; Irigoras Izagirre N; Howat A; Knight BE; Bickerton A; Isotalus HK; Coulthard EJ
Psychopharmacology (Berl); 2018 Dec; 235(12):3443-3450. PubMed ID: 30315362
[TBL] [Abstract][Full Text] [Related]
5. It's all in the type of the task: Dopamine modulates kinematic patterns during competitive vs. cooperative interaction in Parkinson's disease.
Straulino E; Scaravilli T; Bulgheroni M; D'Amico E; Castiello U
Neuropsychologia; 2016 Dec; 93(Pt A):106-115. PubMed ID: 27756693
[TBL] [Abstract][Full Text] [Related]
6. Working memory in Parkinson's disease patients: clinical features and response to levodopa.
Beato R; Levy R; Pillon B; Vidal C; du Montcel ST; Deweer B; Bonnet AM; Houeto JL; Dubois B; Cardoso F
Arq Neuropsiquiatr; 2008 Jun; 66(2A):147-51. PubMed ID: 18545772
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET.
Cools R; Stefanova E; Barker RA; Robbins TW; Owen AM
Brain; 2002 Mar; 125(Pt 3):584-94. PubMed ID: 11872615
[TBL] [Abstract][Full Text] [Related]
8. Effects of L-DOPA on nigral dopamine neurons and local field potential: comparison with apomorphine and muscimol.
Xu D; Karain B; Brantley E; Shi WX
J Pharmacol Exp Ther; 2011 May; 337(2):533-9. PubMed ID: 21330359
[TBL] [Abstract][Full Text] [Related]
9. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease.
Lewis SJ; Slabosz A; Robbins TW; Barker RA; Owen AM
Neuropsychologia; 2005; 43(6):823-32. PubMed ID: 15716155
[TBL] [Abstract][Full Text] [Related]
10. Dopaminergic modulation of prospective memory in Parkinson's disease.
Costa A; Peppe A; Brusa L; Caltagirone C; Gatto I; Carlesimo GA
Behav Neurol; 2008; 19(1-2):45-8. PubMed ID: 18413916
[TBL] [Abstract][Full Text] [Related]
11. Dopamine supports sentence comprehension in Parkinson's Disease.
Grossman M; Glosser G; Kalmanson J; Morris J; Stern MB; Hurtig HI
J Neurol Sci; 2001 Mar; 184(2):123-30. PubMed ID: 11239945
[TBL] [Abstract][Full Text] [Related]
12. Dopaminergic effects on cognitive performance in patients with Parkinson's disease.
Lange KW; Paul GM; Naumann M; Gsell W
J Neural Transm Suppl; 1995; 46():423-32. PubMed ID: 8821078
[TBL] [Abstract][Full Text] [Related]
13. The alpha2 agonist, clonidine, improves spatial working performance in Parkinson's disease.
Riekkinen M; Jäkälä P; Kejonen K; Riekkinen P
Neuroscience; 1999; 92(3):983-9. PubMed ID: 10426538
[TBL] [Abstract][Full Text] [Related]
14. Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease.
Jahanshahi M; Jones CR; Zijlmans J; Katzenschlager R; Lee L; Quinn N; Frith CD; Lees AJ
Brain; 2010 Mar; 133(Pt 3):727-45. PubMed ID: 20305278
[TBL] [Abstract][Full Text] [Related]
15. Cognitive and motor effects of dopaminergic medication withdrawal in Parkinson's disease.
Fern-Pollak L; Whone AL; Brooks DJ; Mehta MA
Neuropsychologia; 2004; 42(14):1917-26. PubMed ID: 15381022
[TBL] [Abstract][Full Text] [Related]
16. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
[TBL] [Abstract][Full Text] [Related]
17. Working memory functioning in medicated Parkinson's disease patients and the effect of withdrawal of dopaminergic medication.
Fournet N; Moreaud O; Roulin JL; Naegele B; Pellat J
Neuropsychology; 2000 Apr; 14(2):247-53. PubMed ID: 10791864
[TBL] [Abstract][Full Text] [Related]
18. Distinct effects of dopamine vs STN stimulation therapies in associative learning and retention in Parkinson disease.
Ventre-Dominey J; Mollion H; Thobois S; Broussolle E
Behav Brain Res; 2016 Apr; 302():131-41. PubMed ID: 26778783
[TBL] [Abstract][Full Text] [Related]
19. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic stimulation facilitates working memory and differentially affects prefrontal low theta oscillations.
Eckart C; Fuentemilla L; Bauch EM; Bunzeck N
Neuroimage; 2014 Jul; 94():185-192. PubMed ID: 24642289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
